Study Examines Erleada Add-on for Non-metastatic Castration-resistant Prostate Cancer

Study Examines Erleada Add-on for Non-metastatic Castration-resistant Prostate Cancer
Patients with castration-resistant prostate cancer (CRPC) who are at high risk for developing metastasis may safely add Erleada (apalutamide) to androgen deprivation therapy without worrying about their quality of life, a new study shows. In February, the treatment became the first androgen receptor inhibitor approved in the United States for non-metastatic CRPC, and additional analysis from the SPARTAN Phase

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *